154 related articles for article (PubMed ID: 12051639)
21. Comparison of different antibodies for detection of progesterone receptor in breast cancer.
Press M; Spaulding B; Groshen S; Kaminsky D; Hagerty M; Sherman L; Christensen K; Edwards DP
Steroids; 2002 Aug; 67(9):799-813. PubMed ID: 12123792
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical assays in prostatic biopsies processed in Bouin's fixative.
Ananthanarayanan V; Pins MR; Meyer RE; Gann PH
J Clin Pathol; 2005 Mar; 58(3):322-4. PubMed ID: 15735170
[TBL] [Abstract][Full Text] [Related]
23. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques.
Taylor CR; Shi SR; Chaiwun B; Young L; Imam SA; Cote RJ
Hum Pathol; 1994 Mar; 25(3):263-70. PubMed ID: 7512074
[TBL] [Abstract][Full Text] [Related]
24. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
26. Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors.
Moazzezy N; Ebrahimi F; Sisakht MM; Yahyazadeh H; Bouzari S; Oloomi M
Asian Pac J Cancer Prev; 2016; 17(1):249-54. PubMed ID: 26838218
[TBL] [Abstract][Full Text] [Related]
27. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
28. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
Soslow RA; Carlson DL; Horenstein MG; Osborne MP
Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
[TBL] [Abstract][Full Text] [Related]
29. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
30. PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status.
Kappes H; Goemann C; Bamberger AM; Löning T; Milde-Langosch K
Pathobiology; 2001; 69(3):136-42. PubMed ID: 11872959
[TBL] [Abstract][Full Text] [Related]
31. A molecular model of antigen retrieval using a peptide array.
Sompuram SR; Vani K; Bogen SA
Am J Clin Pathol; 2006 Jan; 125(1):91-8. PubMed ID: 16482996
[TBL] [Abstract][Full Text] [Related]
32. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer.
Qin Q; Gao F; Jiang W; Tan Q; Mo Q; Wei C
Chin Med J (Engl); 2014; 127(18):3272-7. PubMed ID: 25266526
[TBL] [Abstract][Full Text] [Related]
33. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
35. Methods of antigen recovery vary in their usefulness in unmasking specific antigens in immunohistochemistry.
Frost AR; Sparks D; Grizzle WE
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):236-43. PubMed ID: 10981877
[TBL] [Abstract][Full Text] [Related]
36. Expression of DNA methylation marker of paired-like homeodomain transcription factor 2 and growth receptors in invasive ductal carcinoma of the breast.
Wan Abdul Rahman WF; Fauzi MH; Jaafar H
Asian Pac J Cancer Prev; 2014; 15(19):8441-5. PubMed ID: 25339043
[TBL] [Abstract][Full Text] [Related]
37. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
38. Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms.
Erdem H; Gundogdu B; Ankarali H; Yasar M; Sener E; Oktay M; Bahadir A; Uzunlar AK; Gursan N; Ozaydin I; Sahiner C
Niger J Clin Pract; 2015; 18(5):638-43. PubMed ID: 26096243
[TBL] [Abstract][Full Text] [Related]
39. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.
Aimi F; Procopio MG; Alvarez Flores MT; Brouland JP; Piazzon N; Brajkovic S; Dupouy DG; Gijs M; de Leval L
Virchows Arch; 2019 Sep; 475(3):313-323. PubMed ID: 31267199
[TBL] [Abstract][Full Text] [Related]
40. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
